Amgen beats Q1 expectations, issues solid full-year outlook

Investing.com

02 May

Investing.com - Amgen Inc (NASDAQ:AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.

The biotechnology company posted adjusted earnings per share of $4.90, surpassing analyst estimates of $4.29. Revenue rose 9% YoY to $8.15 billion, slightly above the consensus forecast of $8.09 billion.

"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer.

Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales increased 14%.

Fourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales.

For the full year 2025, Amgen said it expects adjusted EPS of $20.00-$21.20, versus the consensus of $20.63, and revenue of $34.3-$35.7 billion, versus the consensus of $35.102 billion.

The company generated $1.0 billion of free cash flow in Q1, up from $0.5 billion in the same period last year.

Amgen’s shares were flat in after-hours trading following the earnings release.

Related articles

Amgen beats Q1 expectations, issues solid full-year outlook

Amazon reports soft guidance after Q1 results beat

TSX closes in the red ahead of Apple and Amazon earnings

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2532358238"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532358238\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532358238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 04:41","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2532358238","market":"us","top_or_hot":-1,"title":"Amgen beats Q1 expectations, issues solid full-year outlook","media":"Investing.com","content":"<html><body><p>Investing.com - <span><span> Amgen Inc </span></span> (NASDAQ:AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.</p>\n<p>The biotechnology company posted adjusted earnings per share of $4.90, surpassing analyst estimates of $4.29. Revenue rose 9% YoY to $8.15 billion, slightly above the consensus forecast of $8.09 billion.</p>\n<p>\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.</p>\n<p>Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales increased 14%.</p>\n<p>Fourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales.</p>\n<p>For the full year 2025, Amgen said it expects adjusted EPS of $20.00-$21.20, versus the consensus of $20.63, and revenue of $34.3-$35.7 billion, versus the consensus of $35.102 billion.</p>\n<p>The company generated $1.0 billion of free cash flow in Q1, up from $0.5 billion in the same period last year.</p>\n<p>Amgen’s shares were flat in after-hours trading following the earnings release.</p>\n<p>Related articles</p>\n<p>Amgen beats Q1 expectations, issues solid full-year outlook</p>\n<p>Amazon reports soft guidance after Q1 results beat</p>\n<p>TSX closes in the red ahead of Apple and Amazon earnings</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen beats Q1 expectations, issues solid full-year outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen beats Q1 expectations, issues solid full-year outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-02 04:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amgen-beats-q1-expectations-issues-204117596.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -  Amgen Inc  (NASDAQ:AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.\nThe biotechnology company posted adjusted earnings per...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-beats-q1-expectations-issues-204117596.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/amgen-beats-q1-expectations-issues-204117596.html","article_id":"2532358238","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532358238","pubTimestamp":1746132077,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com -  Amgen Inc   reported better-than-expected first-quarter results, driven by strong demand for its products globally.The biotechnology company posted adjusted earnings per share of $4.90, surpassing analyst estimates of $4.29. Revenue rose 9% YoY to $8.15 billion, slightly above the consensus forecast of $8.09 billion.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales increased 14%.For the full year 2025, Amgen said it expects adjusted EPS of $20.00-$21.20, versus the consensus of $20.63, and revenue of $34.3-$35.7 billion, versus the consensus of $35.102 billion.The company generated $1.0 billion of free cash flow in Q1, up from $0","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"安进第一季度超出预期，发布稳健的全年前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"Investing.com -  Amgen Inc  (NASDAQ:AMGN) reported better-than-expected first-quarter results, driven by strong demand for its products globally.\nThe biotechnology company posted adjusted earnings per share of $4.90, surpassing analyst estimates of $4.29. Revenue rose 9% YoY to $8.15 billion, slightly above the consensus forecast of $8.09 billion.\n\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.\nProduct sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales increased 14%.\nFourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales.\nFor the full year 2025, Amgen said it expects adjusted EPS of $20.00-$21.20, versus the consensus of $20.63, and revenue of $34.3-$35.7 billion, versus the consensus of $35.102 billion.\nThe company generated $1.0 billion of free cash flow in Q1, up from $0.5 billion in the same period last year.\nAmgen’s shares were flat in after-hours trading following the earnings release.\nRelated articles\nAmgen beats Q1 expectations, issues solid full-year outlook\nAmazon reports soft guidance after Q1 results beat\nTSX closes in the red ahead of Apple and Amazon earnings","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}